- Home
- CNTX
as 05-09-2025 4:00pm EST
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
| Founded: | 2015 | Country: | United States |
| Employees: | 9 | City: | PHILADELPHIA |
| Market Cap: | 78.0M | IPO Year: | 2021 |
| Target Price: | $6.50 | AVG Volume (30 days): | 94.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.55 - $2.75 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Context Therapeutics Inc. News
CNTX Breaking Stock News: Dive into CNTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
GlobeNewswire
4 days ago
Context Therapeutics Announces Chief Medical Officer Transition
GlobeNewswire
10 days ago
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
MT Newswires
19 days ago
William Blair Initiates Context Therapeutics at Outperform
GlobeNewswire
a month ago
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Zacks
a month ago
Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos
Zacks
a month ago
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains
GlobeNewswire
a month ago
Context Therapeutics to Participate in Upcoming Investor Conferences
Compare CNTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTX Context Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.